Patents Assigned to Tap Holdings Inc.
  • Method for treating sexual dysfunction with apomorphine at specified plasma concentration levels
    Publication number: 20020006933
    Abstract: Methods for administering apomorphine to a patient for the treatment of sexual dysfunctions while reducing undesirable side effects are disclosed. In the methods, the concentration of apomorphine is attained within the patients' plasma of up to 10 nanograms per milliliter. Advantageously, this concentration may be achieved with less than 15% of patients so treated experiencing emesis. Methods of administration are intranasally, by inhalation to the lungs or by oral ingestion.
    Type: Application
    Filed: March 14, 2001
    Publication date: January 17, 2002
    Applicant: TAP Holdings, Inc.
    Inventors: Pramod K. Gupta, John Daniel Bollinger, Yisheng Chen, Jack Yuqun Zheng, Thomas L. Reiland, Dennis Y. Lee
  • Method of treating chronic obstructive pulmonary disease
    Patent number: 6020380
    Abstract: A class of .OMEGA.-substituted-1,4-benzoquinon-2-yl]alkanoic acids are useful in the treatment of chronic obstructive pulmonary disease (COPD). The preferred compound for the method of treatment is 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid or a pharmaceutically acceptable salt, ester or pro-drug thereof.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: February 1, 2000
    Assignee: Tap Holdings Inc.
    Inventor: Anthony Killian
  • LHRH antagonists having lactam groups at the N-terminus
    Patent number: 5516759
    Abstract: Peptides possessing LHRH antagonistic activity, and useful for the controlling the release of LHRH in mammals are decapeptide analogues of LHRH having a lactam group at the N-terminus of the formula ##STR1## where n is 1, 2, or 3 and R.sup.1 is selected from the group consisting of hydrogen, benzyl, 4-chlorobenzyl, 2-methylnaphth-1-yl, 1-methylnaphth-2-yl, and quinolin-3-ylmethyl.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: May 14, 1996
    Assignee: TAP Holdings Inc.
    Inventors: Rolf E. Swenson, Fortuna Haviv, Nicholas A. Mort
  • Cyclic peptide LHRH antagonists
    Patent number: 5508383
    Abstract: A class of cyclic peptides are effective inhibitors of LHRH and are useful in the treatment of disease conditions which are mediated by sex hormones including prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
    Type: Grant
    Filed: March 9, 1994
    Date of Patent: April 16, 1996
    Assignee: Tap Holdings Inc.
    Inventors: Daryl R. Sauer, Fortuna Haviv
  • N-terminus modified analogs of LHRH
    Patent number: 5502035
    Abstract: Decapaptide and undecapaptides substituted on the N-terminal nitrogen atom by acyl groups which include furo-2-yl, isonicotinyl, nicotinyl, 2-, 3-, and 4-quinolinecarbonyl, shikimyl, dihydroshikimyl, and tetrahydrofur-2-oyl are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: March 26, 1996
    Assignee: Tap Holdings Inc.
    Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort
  • LHRH antagonists having modified aminoacyl residues at positions 5 and 6
    Patent number: 5491217
    Abstract: A class of potent LHRH decapeptide antagonists possess N-alkylated aminoacyl residues where the side-chain portion of the residue is a 4-(substimtedamino)phenylalanyl, 4-(substituted-amino)cyclohexylalanyl, or .OMEGA.-(substitutedamino)alkyl group, and additionally the aminoacyl residues at position 5 are N-alkylated on the nitrogen atom of the peptide backbone.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: February 13, 1996
    Assignee: TAP Holding Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Rolf E. Swenson, Daryl R. Sauer